Risedronic acid ( DrugBank: Risedronic acid )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 93 | Primary biliary cholangitis | 1 |
| 95 | Autoimmune hepatitis | 1 |
| 274 | Osteogenesis Imperfecta | 5 |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000012193 | 2013/11/01 | 01/11/2013 | Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of ost ... | Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis - Denosumab versus Bisphosphonate for osteoporosis in patients with PBC Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of ost ... | Osteoporosis in biopsy-proven primary biliary cirrhosis patients pretreated with bisphosphonate | Discontinue the administration of aredoron acid, risedronic acid, and minodronic acid. Then, 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately. Continue the administration of bisphosphonate as heretofore. All patients will take activated vitamin D. Discontinue the administration of aredoron acid, risedronic acid, and minodronic acid. Then, 60mg of ... | Juntendo University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 60 | Not applicable | Japan |
95. Autoimmune hepatitis
Clinical trials : 52 / Drugs : 68 - (DrugBank : 27) / Drug target genes : 18 - Drug target pathways : 111
Showing 1 to 1 of 1 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000013659 | 2014/04/08 | 08/04/2014 | Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH) Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in ... | Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH) - Efficacy of Denosumab for steroid-induced osteoporosis in patients with AIH Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in ... | Biopsy-proven AIH patients who are planned or undergoing oral steroid therapy for more than 3 months Biopsy-proven AIH patients who are planned or undergoing oral steroid therapy for more than 3 months ... | <Test A; Randomization test: 1)2)> In patients pretreated with bisphosphonates; 1) Discontinue the administration of aredoron acid, risedronic acid, or minodronic acid. Then, 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately. <Test A; Randomization test: 1)2)> 2) Continue the administration of bisphosphonate as heretofore. All patients will take activated vitamin D. <Test B; newly intervention> In patients who were not pretreated with bisphosphonates; 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately. In patients pretreated with bisphosphonates; 1) Discontinue the ad | Juntendo University School of Medicine | NULL | Complete: follow-up continuing | 20years-old | 75years-old | Male and Female | 80 | Not applicable | Japan |
274. Osteogenesis Imperfecta
Clinical trials : 91 / Drugs : 101 - (DrugBank : 20) / Drug target genes : 11 - Drug target pathways : 48
Showing 1 to 5 of 5 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-000485-13-DK (EUCTR) | 29/01/2007 | 29/11/2006 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta MedDRA version: 8.1;Level: LLT;Classification code 10031243;Term: Osteogenesis imperfecta Osteogenesis Imperfecta MedDRA version: 8.1;Level: LLT;Classification code 10031243;Term: Osteogenes ... | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Optinate 5 mg filmcoated tablets Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Optinate 5 mg ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Hungary;Finland;Czech Republic;Denmark;Spain | |||
| 2 | EUCTR2004-000485-13-CZ (EUCTR) | 04/10/2006 | 25/08/2006 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Phase 3 | Hungary;Czech Republic;Finland;Spain;Belgium;Denmark | ||
| 3 | EUCTR2004-000485-13-HU (EUCTR) | 25/08/2006 | 14/07/2006 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Finland;Hungary;Czech Republic;Denmark;Spain | |||
| 4 | EUCTR2004-000485-13-BE (EUCTR) | 22/08/2006 | 30/05/2006 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Product Name: Risedronate ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Czech Republic;Hungary;Finland;Spain;Belgium;Denmark | |||
| 5 | EUCTR2004-000485-13-FI (EUCTR) | 28/03/2006 | 10/02/2006 | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate,in Children = 4 to < 16 Years Old with Osteogenesis Imperfecta. - POISE A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study ofOne-year Duratio ... | Osteogenesis Imperfecta | Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Actonel/Optinate 5mg film-coated tablets Product Name: Risedronate sodium 5mg INN or Proposed INN: risedronic acid Product Name: risedronate sodium 2.5mg INN or Proposed INN: risedronic acid Trade Name: Actonel/Optina ... | Procter & Gamble Ltd | NULL | Not Recruiting | Female: yes Male: yes | 124 | Hungary;Finland;Czech Republic;Denmark;Spain |